lpath inc-class a (LPTN) Key Developments
Lpath Inc. - Shareholder/Analyst Call
Jun 3 14
Lpath Inc. - Shareholder/Analyst Call
Lpath Inc., Annual General Meeting, Jun 27, 2014
May 9 14
Lpath Inc., Annual General Meeting, Jun 27, 2014., at 09:00 Pacific Standard Time. Location: 4025 Sorrento Valley Blvd.. Agenda: To elect six directors to hold office until the next annual meeting and until their respective successors are elected and qualified; to ratify the appointment of Moss Adams LLP as independent registered public accounting firm for the fiscal year ending December 31, 2014; to hold a non-binding advisory vote on the compensation of named executive officers; to approve the reincorporation of the company from the State of Nevada to the State of Delaware; and to transact such other business as may properly be brought before the meeting or any adjournment or postponement thereof.
Lpath Inc. Receives Grant from NINDS to Develop its Antibody Therapeutic, Lpathomab
May 5 14
Lpath Inc. received official notification from the National Institutes of Neurological Diseases and Stroke (NINDS) that it has been awarded a $1.7 million, 2.5-year grant to develop its antibody therapeutic, Lpathomab(TM), which is directed against the bioactive lipid lysophosphatidic acid (LPA) for the treatment of traumatic brain injury (TBI). The Phase l amount of $224,000 will fund studies designed to repeat in rats the efficacy previously demonstrated (several times in mice) in a controlled-cortical-impact model of TBI. Contingent on Phase I success, Phase II funds of almost $1.5 million will be used to advance Lpathomab through safety, pharmacology, and toxicology studies needed to file an IND. The National Institutes of Health (NIH) Small Business Innovation Research (SBIR) Fast Track Program was created to provide grants to accelerate the transition from development stage to commercialization of innovative technologies that improve human health and advance the mission of the NIH. The program also aims to foster partnerships among a variety of R&D collaborators working toward these goals. To this end, Lpath has partnered this project with the UCLA Department of Neurosurgery and its prestigious Brain Injury Research Center with Neil Harris, Ph.D., as a co-principal investigator on the project. Lpath has experience in using NIH support to translate bioactive-lipid-targeted products into the clinic through substantial grants from the National Eye Institute for Lpath's iSONEP(TM) program and from the National Cancer Institute for Lpath's ASONEP(TM) program. Currently, Lpath is conducting a Phase 2 clinical trial for iSONEP, which is evaluating the anti-S1P antibody's safety and efficacy in wet-AMD patients that have not responded well to the existing anti-VEGF therapies, Lucentis(R), Avastin(R), and Eylea(R). Lpath entered into an agreement with Pfizer in 2010 that provides Pfizer an exclusive option for a worldwide license to develop and commercialize iSONEP. Additionally, Lpath is independently conducting a Phase 2a trial in renal cell carcinoma patients with ASONEP(TM), an anti-S1P antibody that is formulated for systemic delivery.
Lpath and Walter Reed Army Institute for Research Intiate Efficacy Study Using Lpathomab in Traumatic Brain Injury Models
Apr 23 14
Lpath Inc. and scientists from the Center for Military Psychiatry and Neuroscience, Walter Reed Army Institute of Research (WRAIR), have initiated a study that is the focus of a collaborative research agreement. The collaboration involves the use of Lpathomab(TM), an antibody to lysophosphatidic acid (LPA), in the treatment of brain injury induced by blast overpressure. The investigators at WRAIR are Dr. Joseph Long, a U.S. Army civilian and Chief, Blast Induced Neurotrauma Branch Center for Military Psychiatry and Neuroscience at WRAIR, and Dr. Peetthambaran Arun, from Clinical RM, both of whom have published widely in the area. The use of improvised explosive devices and hand-held grenades in recent wars has increased the incidence of blast traumatic brain injury (TBI), which is a major cause of disability among service members. The prevalence of concussions in soldiers returning from Iraq or Afghanistan has been estimated at approximately 19.6%, and accounts for 150,000 casualties. Blast TBI is the leading source of long-term rehabilitation problems suffered by veterans (e.g. Post-Traumatic Stress Disorder, or PTSD) and is a leading cause of death in military personnel after returning home from theatre. There are currently no FDA-approved drug treatments for any form of TBI.
Lpath To Consider Acquisitions
Mar 18 14
Lpath Inc. (NasdaqCM:LPTN) may consider acquisitions. Lpath has filed a follow-on equity offering in the amount of $23 million, a portion of the net proceeds will be used to invest in or acquire businesses or technologies that are complementary to Lpath, although it has no current plans, commitments or agreements with respect to any acquisitions as of the date of the prospectus of the offering.